3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Breast Neoplasms
4
Neoplasm Metastasis
2
Lung Neoplasms
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Thyroid Cancer, Papillary
1
Prostatic Neoplasms
1
Precancerous Conditions
1
Pleural Effusion, Malignant
1
Neoplasms
1
Lymphatic Metastasis
1
Carcinoma, Non-Small-Cell Lung
1
Barrett Esophagus
1
Adenocarcinoma Of Esophagus
1
Interventions
Iodine-131
5
dabrafenib
4
Vemurafenib
4
Magnetic Resonance Spectroscopy
4
trametinib
3
lenvatinib
3
Transurethral Resection of Prostate
3
Thyrotropin Alfa
3
Thyroidectomy
3
selpercatinib
2
cobimetinib
2
X-Rays
2
Thyroid (USP)
2
Surgical Procedures, Operative
2
Sunitinib
2
Specimen Handling
2
Radiofrequency Ablation
2
Interviews as Topic
2
vandetanib
1
tremelimumab
1
spartalizumab
1
pembrolizumab
1
pazopanib
1
durvalumab
1
delta 24-sterol reductase
1
copanlisib
1
cabozantinib
1
Whole Body Imaging
1
Thyrotropin
1
Thalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Thyroid Cancer, Papillary
×
Spectrum Analysis
×
Clear all
NCT03470259
2024-04-16
TARGET
University Medical Center Groningen
Phase 1
Completed
19 enrolled